Short answer
Fulgent Genetics, Inc. (FLGT) filed an 8-K current report with the SEC on November 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). 44,644-square-foot Needham facility supporting office, R&D, diagnostics, light manufacturing and warehousing.
Fulgent Genetics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- 44,644-square-foot Needham facility supporting office, R&D, diagnostics, light manufacturing and warehousing
- Initial rent $132,071.83 monthly, with 3.0% annual escalators
- 126-month lease term, beginning no later than August 1, 2027, subject to occupancy certification
- Tenant improvement allowance capped at $100 per rentable square foot, reducing upfront build-out burden
- $792,431 cash security deposit and responsibility for repairs and operating costs increase near-term obligations
Item 2.03 · Creation of a Direct Financial Obligation
- Direct financial obligation details incorporated from Item 1.01, indicating a related material agreement
- Investors should review Item 1.01 for borrowing amount, repayment terms, interest rate and purpose
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Fulgent Genetics, Inc. 8-K filings
Get the next FLGT 8-K as it lands
Follow FLGT for push alerts, or ask the research agent what this filing means.